Beilstein J. Nanotechnol.2023,14, 240–261, doi:10.3762/bjnano.14.23
intracellular internalization, and bring advantages over conventional nanocarriers.
Keywords: co-delivery nanoparticles; combinatorial therapy; EGFRTKIresistance; non-small cell lung cancer (NSCLC); overcoming and preventing resistance; Introduction
Among the malignant diseases, lung cancer takes the lead
the adverse effects.
Inhibitors of multiple targets within a single pathway exerting synergistic effects
Amplification, overexpression, and mutation of MET and HER2 are heavily involved in EGFRTKIresistance development, and the cross talk of these receptors is a way to avoid TK inhibition in many
][62].
Further, substantial evidence for the efficacy of EGFR TKIs combined with HER2-targeted therapy in patients with developed EGFRTKIresistance due to HER2 amplification can be found in the literature [63][64][65]. Patients with HER2 gene mutations showing resistance to EGFR TKIs may be sensitive
PDF
Figure 1:
Examples of combinatorial therapy for (left) EGFR-dependent and (right) EGFR-independent TKI resist...